Bluejay Diagnostics reports Q3 revenue decline, SYMON-II clinical trial enrollment advances.

• Bluejay Diagnostics advancing clinical milestones and strategic partnerships • Patient enrollment in SYMON-II clinical trial now 50% completed • Recent private placement transaction completed in October 2025 • Company exploring further financing opportunities • Bluejay Diagnostics focusing on positioning itself for future FDA clearance and product commercialization